Commentary · 21 Feb 2026
Conference abstractPublished 21 Oct 2013
Characterization and targeting of BRIT1 deficiency in Liver cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide, and effective treatment of HCC is of urgent need. In HCC, genomic instability is one of major hallmarks, especially in the tumors at the late stage and metastatic tumors. Thus, we seek to explore if targeting genomic instability and defective DNA repair can effectively inhibit HCC growth. BRIT1/MCPH1 is a recently identified key DNA damage and repair proteins. Recently, we identified that BRIT1 is aberrantly expressed in ~25% of HCC samples. In these samples, the locus of BRIT2 gene showed notable loss of heterogeneity (nearly 50%). We also found a somatic mutation in BRIT1, which occurred in the splicing donor site of intro 10 in the BRIT1 gene, leading to a truncated protein. Functional analysis showed that this mutation can cause failure of foci formation of BRIT1 under irradiation. Importantly, given that BRIT1-deficient cells exhibited defective DNA repair described above, our in vitro studies showed that the BRIT1-deficient HCC cells are more sensitive to olaparib, the inhibitor of poly (ADP-ribose) polymerase (PARPi), compared to the BRIT1-proficient cells. Furthermore, we also test the inhibitory effect of olaparib in the xenograft mouse model, and found that PARPi can significantly suppress tumor growth of HCC xenografts. Collectively, our results clearly demonstrate that BRIT1 is mutated and aberrantly expressed in HCC, and targeting BRIT1 deficiency by PARP inhibitors in combination with other anti-cancer agents may provide novel and effective targeted therapies to treat BRIT1-deficient HCC.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Kaiyi Li”
